{
    "nct_id": "NCT05783830",
    "title": "A Phase 0, Open-label, Non-controlled Study to Evaluate the Pharmacokinetics of a Single Intravenous Microdose of ACD856 in Healthy Volunteers",
    "status": "COMPLETED",
    "last_update_time": "2023-03-23",
    "description_brief": "This is a Phase 0, open-label, non-controlled, single-centre study designed to evaluate the pharmacokinetics (PK) and safety and tolerability of a single, bolus intravenous (iv) injection of a microdose of ACD856 in healthy subjects.",
    "description_detailed": "N/A",
    "phase": [
        "EARLY_PHASE1"
    ],
    "study_type": "INTERVENTIONAL",
    "primary_purpose": "TREATMENT",
    "results": null,
    "target_category": "disease-targeted small molecule",
    "drug": [
        "ACD856 (ACD-856) \u2014 small-molecule positive allosteric modulator of TrkA/TrkB/TrkC (triazinetrione class)"
    ],
    "placebo": [],
    "explanation_target": [
        "Reason: The trial tests ACD856, which is a small-molecule positive allosteric modulator of neurotrophin (Trk) receptors intended to potentiate BDNF/NGF signaling and improve neuroplasticity and cognition \u2014 i.e., it is a pharmacologic modulator of a disease-relevant target rather than a biologic or a purely symptomatic neuropsychiatric agent. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Act: I searched the literature to confirm the drug identity and mechanism. ACD856 is described as a TrkA/TrkB/TrkC positive allosteric modulator developed by AlzeCure for cognitive dysfunction/Alzheimer\u2019s disease; a Phase 0 intravenous microdose PK/safety study has been conducted. Key sources: Alzforum and PubMed Phase 0/PK report. \ue200cite\ue202turn0search1\ue202turn0search0\ue201",
        "Reflect: Mapping to the provided categories: (1) Not a biologic (ACD856 is a small molecule), so not 'disease-targeted biologic.' (2) It modulates disease-relevant neurotrophin receptors (Trk), fitting 'disease-targeted small molecule.' (3) Although it is developed as a cognitive enhancer, its mechanism targets neurotrophic signaling and shows neuroprotective/neurorestorative effects in preclinical studies \u2014 supporting classification as a disease-targeted small molecule rather than only a symptomatic cognitive enhancer. Supporting preclinical/clinical statements: neuroprotective and pro-cognitive effects and the microdose PK study. \ue200cite\ue202turn0search5\ue202turn0search2\ue201",
        "Web search results / supporting references (selected): 1) PubMed summary of the microdose Phase 0 PK/safety study describing the IV microdose and PK findings. \ue200cite\ue202turn0search0\ue201 2) Alzforum summary of pharmacology showing Trk potentiation, pro-cognitive effects, and trial history. \ue200cite\ue202turn0search1\ue201 3) Preclinical paper describing neuroprotective and neurotrophic effects (BDNF increase) and rationale for cognitive dysfunction treatment. \ue200cite\ue202turn0search5\ue201 4) Alzheimer\u2019s & Dementia (Wiley) overview of ACD856 development and mechanism. \ue200cite\ue202turn0search2\ue201",
        "Notes on ambiguity: Some sources emphasize ACD856 as a 'cognitive enhancer' in clinical development; this is true descriptively (it aims to improve cognition), but mechanistically it is a small-molecule modulator of disease-relevant Trk neurotrophin receptors (supporting 'disease-targeted small molecule' as the best fit under the provided category definitions). If you prefer classification by intended clinical effect rather than mechanism, it could alternatively be labeled 'cognitive enhancer' \u2014 flagging this as a possible alternate interpretation."
    ],
    "agent_type": "L) Growth Factors and Hormones",
    "explanation_agent": [
        "Reason: The investigational drug ACD856 is a small-molecule positive allosteric modulator of Trk neurotrophin receptors (TrkA/TrkB/TrkC) and acts by potentiating NGF/BDNF neurotrophic signaling to enhance neuroplasticity and cognition \u2014 this mechanism targets neurotrophic/growth-factor pathways rather than amyloid, tau, inflammation, etc. \ue200cite\ue202turn0search1\ue202turn0search5\ue201",
        "Act: Assigned category 'L) Growth Factors and Hormones' because Trk receptors are receptors for neurotrophins (growth factors) and the compound directly modulates Trk kinase activity; supporting sources include Alzforum and multiple peer-reviewed reports describing ACD856 as a Trk positive allosteric modulator and the Phase 0 IV microdose PK/safety study. \ue200cite\ue202turn0search1\ue202turn0search2\ue202turn0search4\ue201",
        "Reflect: Confirmed that this is not primarily an anti-amyloid, anti-tau, inflammatory, or purely symptomatic neurotransmitter-receptor intervention. Although ACD856 produces pro-cognitive and neuroprotective effects (which also relate to synaptic plasticity), its proximate biological target is the neurotrophin/Trk growth-factor signaling pathway, making 'L) Growth Factors and Hormones' the most specific CADRO match. Key supporting references: AlzeCure/Wiley overview (ACD856 mechanism), preclinical neuroprotective data, and the Phase 0 microdose PK study. \ue200cite\ue202turn0search0\ue202turn0search5\ue202turn0search2\ue201"
    ]
}